Brainsway Ltd. BWAY

Company Overview

BrainsWay Ltd. is a global medical technology company focused on the development and commercialization of non-invasive neuromodulation treatments. The company operates within the medical devices and mental health therapeutics industries, specializing in transcranial magnetic stimulation (TMS). BrainsWay’s core offering is its proprietary Deep TMS technology, designed to stimulate deeper and broader regions of the brain than conventional TMS systems. The company primarily serves psychiatric clinics, hospitals, and research institutions treating patients with major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and other neuropsychiatric conditions.

Founded in 2003, BrainsWay originated as a spinoff from academic research led by its founder, Prof. Abraham Zangen, aimed at improving the clinical efficacy of brain stimulation technologies. The company gradually transitioned from research and development to full commercial operations, achieving multiple regulatory clearances and expanding internationally. BrainsWay is publicly listed on NASDAQ and the Tel Aviv Stock Exchange, reflecting its evolution from an Israel-based research venture into a globally active medtech company.